PT - JOURNAL ARTICLE AU - Nathan J. Edwards AU - Rebecca Widrick AU - Richard Potember AU - Mike Gerschefske TI - Quantifying Respiratory Airborne Particle Dispersion Control Through Improvised Reusable Masks AID - 10.1101/2020.07.12.20152157 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.12.20152157 4099 - http://medrxiv.org/content/early/2020/07/14/2020.07.12.20152157.short 4100 - http://medrxiv.org/content/early/2020/07/14/2020.07.12.20152157.full AB - Objective To determine the effectiveness of non-medical grade washable masks or face coverings in controlling airborne dispersion from exhalation (both droplet and aerosol), and to aid in establishing public health strategies on the wearing of masks to reduce COVID-19 transmission.Design This comparative effectiveness study using an exhalation simulator to conduct 94 experiment runs with combinations of 8 different fabrics, 5 mask designs, and airflows for both talking and coughing.Setting Non-airtight fume hood and multiple laser scattering particle sensors.Participants No human participants.Exposure 10% NaCl nebulized solution delivered by an exhalation simulator through various masks and fabrics with exhalation airflows representative of “coughing” and “talking or singing.”Main Outcomes and Measures The primary outcome was reduction in aerosol dispersion velocity, quantity of particles, and change in dispersion direction. Measurements used in this study included peak expiratory flow (PEF), aerosol velocity, concentration area under curve (AUC), and two novel metrics of expiratory flow dispersion factor (EDF) and filtration efficiency indicator (FEI).Results Three-way multivariate analysis of variance establishes that factors of fabric, mask design, and exhalation breath level have a statistically significant effect on changing direction, reducing velocity or concentration (Fabric: P = < .001, Wilks’ Λ = .000; Mask design: P = < .001, Wilks’ Λ = .000; Breath level: P = < .001, Wilks’ Λ = .004). There were also statistically significant interaction effects between combinations of all primary factors.Conclusions and Relevance The application of facial coverings or masks can significantly reduce the airborne dispersion of aerosolized particles from exhalation. The results show that wearing of non-medical grade washable masks or face coverings can help increase the effectiveness of non-pharmaceutical interventions (NPI) especially where infectious contaminants may exist in shared air spaces. However, the effectiveness varies greatly between the specific fabrics and mask designs used.STRENGTHS AND LIMITATIONS OF THIS STUDYThe strength of this study is that it offers quantitative evidence on the effectiveness of wearing non-medical improvised masks in controlling airborne dispersion of particles from exhalation.Study can aid in establishing public health strategy that encourage the wearing of masks or face coverings for reducing airborne transmission of infectious disease in shared air spaces.A limitation of this study is that is uses an exhalation simulator with the PPE industry standard NaCl test solution for particle generation rather than a clinical study with exhalation of biomaterial particles.The particle sensors used had a limited ability to detect fast moving aerosol clouds from coughing or talking with no-mask applied.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by independent research and development funding provided by the author's organization, The MITRE Corporation. Copyright 2020 The MITRE Corporation. ALL RIGHTS RESERVED. Approved for Public Release; Distribution Unlimited. Public Release Case Number 20-1583Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human participants, IRB not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEmpirical data may be made available by formal request to author's organization